Kuros Biosciences: Funding, Investors & Team (Sep 2026)

Kuros Biosciences AG is a Swiss-based company focused on the development of innovative products for tissue repair and regeneration. Founded in 2000 as a spin-off of the Eidgenössische Technische Hochschule Zürich (ETHZ), Kuros has developed a pipeline of products based upon its proprietary technology platforms. These platforms were developed from work carried out at ETHZ, at the University of Zürich and at the California Institute of Technology (CalTech). In addition, in early 2017 Kuros acquired Xpand Biotechnology to gain access to its MagnetOs family of bone graft substitutes and the associated surface science technology. Kuros has attractive commercial prospects in key market segments as well as an EU hub for future clinical and distribution operations. The company is in transition to commercial stage with one product having marketing approval in the EU and US and further product expected to achieve EU approval this year. MagnetOs is approved for sale in the EU for orthopedic, spine and dental applications, and in the US for posterolateral spinal fusion. In addition, a putty formulation is being prepared for submission in the EU and the US in the second half of this year. Neuroseal, a novel biomaterial for dural sealing, is Kuros’ second product and currently under review for CE marking in the EU. Kuros has also assembled a pipeline of clinical stage programs in various stages of development and amassed significant clinical and preclinical data in a number of indications and applications primarily in the area of orthobiologics. The Company has enrolled over 600 patients in multinational clinical trials, and has generated promising safety and efficacy in a number of significant indications.

Kuros Biosciences has raised $6.2M across 1 round on record. The most recent is a Post-IPO Equity of $6.2M announced in Sep 2022.

Kuros Biosciences' most recent funding round on record is a Post-IPO Equity of $6.2M, announced in Sep 2022.

Didier Cowling is listed as CEO at Kuros Biosciences.

Kuros Biosciences is based in Schlieren, Zurich, Switzerland.

Kuros Biosciences is in the 11-50 employee band.

Kuros Biosciences' latest round of $6.2M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.